Movement of Poly-ADP Ribose (PARP) Inhibition Into Frontline Treatment ...

January 1, 2020

PARP inhibitors show promise in frontline treatment for advanced ovarian cancer, especially for BRCA-associated and HRD tumors. FDA approvals include olaparib for BRCA-associated cancers and niraparib for all patients. Factors like FDA indication, dosing, toxicity, and cost influence treatment decisions. Ongoing research explores PARP inhibitor resistance and combination therapies.

Related Clinical Trials

A Study to Examine Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer.

A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer

A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy

Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients

Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)

A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

Reference News

pmc.ncbi.nlm.nih.gov

Movement of Poly-ADP Ribose (PARP) Inhibition Into Frontline Treatment ...